Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Oteseconazole

FDA-approved product (capsule, oral), marketed as Vivjoa.

Registered studies
6
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Oteseconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Vulvovaginal candidiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC06; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Oteseconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Oteseconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi

    NCT07804368 · start 2026-12-01

    Registered record
    Registry ID
    NCT07804368
    Conditions
    Coccidioidomycosis; Blastomycosis; Histoplasmosis; Dimorphic Fungal Infection; Endemic Mycoses
    Interventions
    Oteseconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2028-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoccidioidomycosis; Blastomycosis; Histoplasmosis; Dimorphic Fungal Infection +1 more
    InterventionOteseconazole
    PhasePhase 2
    Registry statusNot yet recruiting

  • Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）

    NCT07044947 · start 2025-08-10

    Registered record
    Registry ID
    NCT07044947
    Conditions
    Vulvovaginal Candidiasis
    Interventions
    Oteseconazole (VT-1161) 150mg capsule
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-08-10
    Completion
    2030-08-10
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvovaginal Candidiasis
    InterventionOteseconazole (VT-1161) 150mg capsule
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)

    NCT06666322 · start 2025-05-28

    Registered record
    Registry ID
    NCT06666322
    Conditions
    Hiv; Cryptococcal Meningitis
    Interventions
    Standard of care; Oteseconazole - antifungal therapy 1; Turletricin injection - antifungal therapy 2; Turletricin Injection - antifungal therapy 3; Oteseconazole with Flucytosine - antifungal therapy 4
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-05-28
    Completion
    2032-04-21
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv; Cryptococcal Meningitis
    InterventionStandard of care; Oteseconazole - antifungal therapy 1; Turletricin injection - antifungal therapy 2; Turletricin Injection - antifungal therapy 3 +1 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

    NCT03840616 · start 2019-03-13

    Registered record
    Registry ID
    NCT03840616
    Conditions
    Recurrent Vulvovaginal Candidiasis
    Interventions
    Oteseconazole (VT-1161) 150mg capsule; Fluconazole 150mg capsule; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-13
    Completion
    2020-12-02
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Vulvovaginal Candidiasis
    InterventionOteseconazole (VT-1161) 150mg capsule; Fluconazole 150mg capsule; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

    NCT03561701 · start 2018-08-23

    Registered record
    Registry ID
    NCT03561701
    Conditions
    Recurrent Vulvovaginal Candidiasis
    Interventions
    Oteseconazole (VT-1161); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-23
    Completion
    2021-08-03
    Enrolment
    425

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Vulvovaginal Candidiasis
    InterventionOteseconazole (VT-1161); Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

    NCT03562156 · start 2018-08-16

    Registered record
    Registry ID
    NCT03562156
    Conditions
    Recurrent Vulvovaginal Candidiasis
    Interventions
    Oteseconazole (VT-1161); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-16
    Completion
    2021-08-06
    Enrolment
    438

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Vulvovaginal Candidiasis
    InterventionOteseconazole (VT-1161); Placebo
    PhasePhase 3
    Registry statusCompleted